Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line

被引：38

作者：

Miyata, Haruo ^{[1
]}

Ashizawa, Tadashi ^{[1
]}

Iizuka, Akira ^{[1
]}

Kondou, Ryota ^{[1
]}

Nonomura, Chizu ^{[1
]}

Sugino, Takashi ^{[3
]}

Urakami, Kenichi ^{[2
]}

Asai, Akira ^{[6
]}

Hayashi, Nakamasa ^{[4
]}

Mitsuya, Koichi ^{[4
]}

Nakasu, Yoko ^{[4
]}

Yamaguchi, Ken ^{[5
]}

Akiyama, Yasuto ^{[1
,4
]}

机构：

[1] Shizuoka Canc Ctr Hosp, Div Immunotherapy, 1007 Shimonagakubo,Nagaizumi Cho, Shizuoka 4118777, Japan

[2] Shizuoka Canc Ctr Hosp, Shizuoka Canc Ctr Res Inst, Canc Diagnost Div, Shizuoka, Japan

[3] Shizuoka Canc Ctr Hosp, Div Pathol, Shizuoka, Japan

[4] Shizuoka Canc Ctr Hosp, Div Neurosurg, Shizuoka, Japan

[5] Shizuoka Canc Ctr Hosp, Off President, Shizuoka, Japan

[6] Univ Shizuoka, Grad Sch Pharmaceut Sci, Shizuoka 4228526, Japan

来源：

CANCER GENOMICS & PROTEOMICS | 2017年 / 14卷 / 01期

关键词：

STAT3; inhibitor; mTOR inhibitor; temozolomide resistance; glioblastoma; ANTITUMOR-ACTIVITY; RAPAMYCIN; MUTATIONS; RAS/RAF/MEK/ERK; RADIOTHERAPY; CONCOMITANT; ACTIVATION; EVOLUTION; CANCER; TRIAL;

D O I：

10.21873/cgp.20021

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TMZ-R Background: Temozolomide-resistant (TMZ-R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed. Materials and Methods: The efficacy of a combination treatment of STAT3 inhibitor, STX-0119, with rapamycin was investigated against our established TMZ-resistant U87 cell line. Results: The growth-inhibitory effect of the combination treatment was significant against the TMZ-R U87 cell line (IC50: 78 mu M for STX-0119, 30.5 mu M for rapamycin and 11.3 mu M for combination of the two). Western blotting analysis demonstrated that the inhibitory effect of STX-0119 on S6 and 4E-BP1 activation through regulation of YKL-40 expression occurred in addition to the inhibitory effect of rapamycin against the mTOR pathway. Conclusion: These results suggest that the STAT3 pathway is associated with the mTOR downstream pathway mediated by YKL-40 protein, and the combination therapy of the STAT3 inhibitor and rapamycin could be worth developing as a novel therapeutic approach against TMZ-resistant relapsed gliomas.

引用

页码：83 / 91

页数：9

共 38 条

[31] Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer [J].

Sato, T. ;

Nakashima, A. ;

Guo, L. ;

Coffman, K. ;

Tamanoi, F. .

ONCOGENE, 2010, 29 (18) :2746-2752

[32] A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy [J].

Stroebele, Stephanie ;

Schneider, Matthias ;

Schneele, Lukas ;

Siegelin, Markus D. ;

Nonnenmacher, Lisa ;

Zhou, Shaoxia ;

Karpel-Massle, Georg ;

Westhoff, Mike-Andrew ;

Halatsch, Marc-Eric ;

Debatin, Klaus-Michael .

PLOS ONE, 2015, 10 (06)

[33] Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma [J].

Stupp, R ;

Mason, WP ;

van den Bent, MJ ;

Weller, M ;

Fisher, B ;

Taphoorn, MJB ;

Belanger, K ;

Brandes, AA ;

Marosi, C ;

Bogdahn, U ;

Curschmann, J ;

Janzer, RC ;

Ludwin, SK ;

Gorlia, T ;

Allgeier, A ;

Lacombe, D ;

Cairncross, JG ;

Eisenhauer, E ;

Mirimanoff, RO ;

Van Den Weyngaert, D ;

Kaendler, S ;

Krauseneck, P ;

Vinolas, N ;

Villa, S ;

Wurm, RE ;

Maillot, MHB ;

Spagnolli, F ;

Kantor, G ;

Malhaire, JP ;

Renard, L ;

De Witte, O ;

Scandolaro, L ;

Vecht, CJ ;

Maingon, P ;

Lutterbach, J ;

Kobierska, A ;

Bolla, M ;

Souchon, R ;

Mitine, C ;

Tzuk-Shina, T ;

Kuten, A ;

Haferkamp, G ;

de Greve, J ;

Priou, F ;

Menten, J ;

Rutten, I ;

Clavere, P ;

Malmstrom, A ;

Jancar, B ;

Newlands, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :987-996

[34] Next generation sequencing approach for detecting 491 fusion genes from human cancer [J].

Urakami, Kenichi ;

Shimoda, Yuji ;

Ohshima, Keiichi ;

Nagashima, Takeshi ;

Serizawa, Masakuni ;

Tanabe, Tomoe ;

Saito, Junko ;

Usui, Tamiko ;

Watanabe, Yuko ;

Naruoka, Akane ;

Ohnami, Sumiko ;

Ohnami, Shumpei ;

Mochizuki, Tohru ;

Kusuhara, Masatoshi ;

Yamaguchi, Ken .

BIOMEDICAL RESEARCH-TOKYO, 2016, 37 (01) :51-62

[35] Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 [J].

Wen, Patrick Y. ;

Chang, Susan M. ;

Lamborn, Kathleen R. ;

Kuhn, John G. ;

Norden, Andrew D. ;

Cloughesy, Timothy F. ;

Robins, H. Ian ;

Lieberman, Frank S. ;

Gilbert, Mark R. ;

Mehta, Minesh P. ;

Drappatz, Jan ;

Groves, Morris D. ;

Santagata, Sandro ;

Ligon, Azra H. ;

Yung, W. K. Alfred ;

Wright, John J. ;

Dancey, Janet ;

Aldape, Kenneth D. ;

Prados, Michael D. ;

Ligon, Keith L. .

NEURO-ONCOLOGY, 2014, 16 (04) :567-578

[36] Association of MSH6 mutation with glioma susceptibility, drug resistance and progression [J].

Xie, Chaoran ;

Sheng, Hansong ;

Zhang, Nu ;

Li, Shiting ;

Wei, Xiangyu ;

Zheng, Xuesheng .

MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (02) :236-240

[37] NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells [J].

Yu, Zhiyun ;

Xie, Guifang ;

Zhou, Guangtong ;

Cheng, Ye ;

Zhang, Guangtao ;

Yao, Guangming ;

Chen, Yong ;

Li, Yunqian ;

Zhao, Gang .

CANCER LETTERS, 2015, 367 (01) :58-68

[38] Oroxylin A induces autophagy in human malignant glioma cells via the mTOR-STAT3-Notch signaling pathway [J].

Zou, Meijuan ;

Hu, Chen ;

You, Qidong ;

Zhang, Aixia ;

Wang, Xuerong ;

Guo, Qinglong .

MOLECULAR CARCINOGENESIS, 2015, 54 (11) :1363-1375

← 1 2 3 4 →